GNRH1 and prostate carcinoma: We searched the electronic databases (MEDLINE, Web of Science, Cochrane Library, and Scopus) in the last twenty years for trials analyzing GnRH antagonist and agonist in terms of cardiovascular impact and safety (prostate cancer and cardiovascular events and degarelix or LHRH agonists).